Equities Analysts Set Expectations for TCRX FY2026 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Investment analysts at HC Wainwright lowered their FY2026 earnings estimates for TScan Therapeutics in a research note issued on Wednesday, August 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.91) for the year, down from their prior estimate of ($0.88). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for TScan Therapeutics’ FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.91) EPS, FY2029 earnings at ($0.80) EPS and FY2030 earnings at ($0.16) EPS.

Several other brokerages have also recently weighed in on TCRX. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Friday, July 17th. Benchmark reiterated a “buy” rating on shares of TScan Therapeutics in a research report on Thursday. Wedbush reissued an “outperform” rating and set a $5.00 price target on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Wall Street Zen cut TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $6.00.

TScan Therapeutics Price Performance

NASDAQ:TCRX opened at $0.77 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.65 and a quick ratio of 6.65. The company has a market cap of $50.45 million, a P/E ratio of -0.85 and a beta of 1.06. The firm’s fifty day moving average price is $0.90 and its two-hundred day moving average price is $1.01. TScan Therapeutics has a one year low of $0.72 and a one year high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.02. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 97.00%. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.88 million.

Hedge Funds Weigh In On TScan Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TCRX. Boothbay Fund Management LLC boosted its stake in shares of TScan Therapeutics by 50.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after purchasing an additional 8,121 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in TScan Therapeutics in the fourth quarter valued at approximately $25,000. Landscape Capital Management L.L.C. acquired a new position in shares of TScan Therapeutics during the second quarter valued at about $25,000. HRT Financial LP bought a new position in shares of TScan Therapeutics during the 4th quarter worth about $26,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of TScan Therapeutics during the 1st quarter worth about $28,000. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.